

Amendment

February Session, 2014

LCO No. 5026

SB0018605026HD0

Offered by:

REP. MEGNA, 97th Dist. SEN. LOONEY, 11th Dist. SEN. CRISCO, 17th Dist.

To: Senate Bill No. 186 File No. 58 Cal. No. 416

(As Amended by Senate Amendment Schedule "A")

"AN ACT CONCERNING DISPENSATION AND INSURANCE COVERAGE OF A PRESCRIBED DRUG DURING REVIEW OF AN ADVERSE DETERMINATION OR A FINAL ADVERSE DETERMINATION."

Strike subparagraph (C) of subdivision (1) of subsection (b) of section 1 in its entirety and insert the following in lieu thereof:

3 "(C) (i) If the review under subparagraph (A) of this subdivision is a 4 review of a grievance involving a prospective review request relating

5 to the dispensing of a drug for a chronic disease, other than a schedule

6 II or III controlled substance, that is prescribed by a licensed

7 participating provider who is a specialist in such chronic disease, the

8 health carrier shall issue, upon the request of such participating

9 provider, an electronic authorization to the covered person's pharmacy

10 for the dispensing of a temporary supply of such drug sufficient for

SB 186 Amendment

the duration of such review until the covered person has been notified

- 12 of the review decision. Such authorization shall include confirmation
- of the availability of payment for such supply of such drug.
- 14 (ii) Not later than twenty-four hours after the health carrier has
- 15 <u>issued such authorization to the pharmacy, such health carrier shall</u>
- 16 confirm with such participating provider the provider's concurrence
- 17 with the dispensing of such temporary supply of such drug. If such
- 18 participating provider does not concur, the health carrier shall cancel
- 19 such authorization.
- 20 (iii) The provisions of this subparagraph shall not apply to a
- 21 grievance or review of an adverse determination under this section
- 22 concerning the substitution of a generic drug or another brand name
- 23 drug for a prescribed brand name drug unless the prescribing licensed
- 24 participating provider has specified that there shall be no substitution
- 25 for the specified brand name drug."
- 26 Strike subdivision (4) of subsection (c) of section 2 in its entirety and
- 27 insert the following in lieu thereof:
- 28 "(4) (A) If the review under subdivision (1) of this subsection is a
- 29 review of a grievance involving a prospective review request relating
- 30 to the dispensing of a drug for a chronic disease, other than a schedule
- 31 <u>II or III controlled substance, that is prescribed by a licensed</u>
- 32 participating provider who is a specialist in such chronic disease, the
- 33 <u>health carrier shall issue, upon the request of such participating</u>
- 34 provider, an electronic authorization to the covered person's pharmacy
- 35 for the dispensing of a temporary supply of such drug sufficient for
- 36 <u>the duration of such review until the covered person has been notified</u>
- 37 of the review decision. Such authorization shall include confirmation
- 38 of the availability of payment for such supply of such drug.
- 39 (B) Not later than twenty-four hours after the health carrier has
- 40 <u>issued such authorization to the pharmacy, such health carrier shall</u>
- 41 confirm with such participating provider the provider's concurrence

SB 186 Amendment

with the dispensing of such temporary supply of such drug. If such participating provider does not concur, the health carrier shall cancel such authorization.

45 (C) The provisions of this subdivision shall not apply to a grievance 46 or review of an adverse determination under this section concerning 47 the substitution of a generic drug or another brand name drug for a 48 prescribed brand name drug unless the prescribing licensed 49 participating provider has specified that there shall be no substitution 50 for the specified brand name drug."